Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Art on Disasters to heal communities
2014-05-27

 
Fadzai Nyamusamba showing interest in the work: "Working on fire". This artwork was painted and donated by Mariette Pretorius, a professional artist from Bloemfontein. This art piece will be displayed at the South African National Disaster Management Centre in Pretoria.
Photo: Supplied
The Disaster Management Training and Education Centre for Africa (DiMTEC) at our university, recently launched its Art on Disasters initiative at the Gallery on Leviseur in Bloemfontein. 

Disasters have a devastating effect on societies and are accompanied by fear, uncertainties and often post-traumatic stress disorders. The creative arts have the ability to comfort survivors and those affected by tragedy. Amid disaster, art serves as a memorial, aids in the healing process and helps these communities to interpret their emotions. 

This is precisely the main focus of the Art on Disasters project. It aims to develop paintings, sculptures, dramas, theatre productions, poetry and music in collaboration with artists. These productions will then be presented to communities at risk of, or affected by, disasters, to create awareness and foster healing. 

Furthermore, the initiative will conduct research on art as a form of therapy and co-ordinate rehabilitation experts to assist the relevant communities. The artworks collected by the project, will be sold or auctioned to help raise funds. The proceeds will then be donated to a worthy cause as part of DiMTEC’s commitment to community service. 

The project will help console and heal communities and aspire to generate greater resilience to trauma. It will also give humanitarian workers the opportunity to advocate for disaster risk reduction and offer them an opportunity for psychological debriefing after attending to affected communities. 

“We will collect different categories of art related to all forms of disasters. These include paintings, photography, sculptures, poetry, music, theatre productions and short stories,” said Dr Andries Jordaan, Director of DiMTEC. “Stephanie Peters, Thomas Hart Benton, Tania Kovats and Medhi Naimi are just a few of the many artists that paint on man-made and natural disasters. They are artists that believe in art therapy as a form of self-expression, well-being and recovery,” he added. 

For more information about this initiative, or to possibly contribute as an artist, please contact Olivia Kunguma from DiMTEC on +27(0)51 401 9699 or kungumao@ufs.ac.za .

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept